Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Signs Exclusive Digital PCR Licensing Agreement with Genomic Nanosystems

NEW YORK (GenomeWeb News) – Sequenom said today that it has obtained exclusive rights to Genomic Nanosystems’ digital PCR technologies and techniques.
The agreement gives Sequenom exclusive rights to use the digital PCR methods for non-invasive, prenatal diagnostic testing and sample analysis on any platform. In addition, the company will have exclusive rights to use digital PCR in conjunction with mass spectrometry for all commercial, diagnostic, or research applications except second-generation sequencing.
In a statement issued today, Sequenom CEO Harry Stylli said that the agreement — and another digital PCR licensing agreement signed last week — serve to enhance Sequenom’s intellectual property position for non-invasive prenatal diagnostic testing. He also noted that the company plans to develop a system that combines its proprietary MassARRAY system with digital PCR for use in other areas, including the genomic analysis business and cancer research and diagnostics.
Financial terms of the agreement were not disclosed.
Genomic Nanosystems is a wholly owned subsidiary of Cytonix Corporation.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more